Vir Biotechnology, Inc. Restructuring Charges
Vir Biotechnology, Inc. (VIR) reported Restructuring Charges of $34.99 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-23
- Vir Biotechnology, Inc. restructuring charges for the quarter ending 2024-09-30 was $12.71M.
- Vir Biotechnology, Inc. restructuring charges for the quarter ending 2024-06-30 was $26.27M.
- Vir Biotechnology, Inc. restructuring charges for the quarter ending 2024-03-31 was -$48.00K.
- Vir Biotechnology, Inc. restructuring charges for fiscal 2024 was $34.99M, a 158.09% increase from fiscal 2023.
- Vir Biotechnology, Inc. restructuring charges for fiscal 2023 was $13.56M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-12-31 | $34.99M 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $12.71M 10-Q · filed 2024-11-04 | $38.99M derived: sum of 2 quarters · filed 2024-11-04 | $38.94M derived: sum of 3 quarters · filed 2024-11-04 | |
| 2024-06-30 | $26.27M 10-Q · filed 2024-11-04 | $26.23M derived: sum of 2 quarters · filed 2024-11-04 | ||
| 2024-03-31 | -$48.00K 10-Q · filed 2024-11-04 | |||
| 2023-12-31 | $13.56M 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |